Last reviewed · How we verify

Multiple ascending dose of X842

Cinclus Pharma AG · Phase 1 active Small molecule

Multiple ascending dose of X842 is a Small molecule drug developed by Cinclus Pharma AG. It is currently in Phase 1 development. Also known as: X842.

At a glance

Generic nameMultiple ascending dose of X842
Also known asX842
SponsorCinclus Pharma AG
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Multiple ascending dose of X842

What is Multiple ascending dose of X842?

Multiple ascending dose of X842 is a Small molecule drug developed by Cinclus Pharma AG.

Who makes Multiple ascending dose of X842?

Multiple ascending dose of X842 is developed by Cinclus Pharma AG (see full Cinclus Pharma AG pipeline at /company/cinclus-pharma-ag).

Is Multiple ascending dose of X842 also known as anything else?

Multiple ascending dose of X842 is also known as X842.

What development phase is Multiple ascending dose of X842 in?

Multiple ascending dose of X842 is in Phase 1.

Related